To main content (press Enter)
Takeda

Takeda Lessines saves 600 million litres of water per year

In March 2021, the pharmaceutical company Takeda inaugurated a new wastewater recycling facility in Lessines. This investment will result in a 90% reduction in the consumption of drinking water at the site. This represents 600,000 cubic metres of water per year, equal to the average amount of drinking water consumed by almost 18,000 people.

After treatment, the purified wastewater meets the strictest quality requirements, allowing it to be reused in the drug manufacturing process.

Also interesting

Aptaskil 3

aptaskil Competence Centre expands and goes digital to better meet talent needs in chemistry, biopharma and biotech

aptaskil, the competence centre for the chemical, biopharmaceutical, and biotechnological professions in Seneffe, is entering a new era with new infrastructure, larger training capacity and a major shift to digitalization of teaching methods. Over 8 million euros have been invested to upgrade the initial infrastructure, adding 1,400 m² of training facilities including clean rooms and laboratories, allowing the centre to train up to 6,000 learners each year (job seekers, workers, students), using, among other things, the latest virtual reality applications. The official opening was attended by Willy Borsus, Vice-President of Wallonia and Minister for Competence Centres.

Read more
PR caption

Visit of the Belgian sovereigns Philippe and Mathilde to Afrigen Biologics

During their state visit to South Africa last March, Queen Mathilde and King Philippe visited the Afrigen biologics facilities in Cape Town to learn more about how two Belgian companies, Univercells and Etherna, are supporting the development of the first African-owned mRNA COVID-19 vaccine to further discuss cooperation and partnership between the two countries and focus, among other things, on business and development.

Read more
One stop shop

Xpress Biologics moves up a gear with Polyplus & SSB

Belgian CDMO Xpress Biologics becomes a strategic enabler of gene therapy production for Polyplus (now to be acquired by Sartorius Stedim Biotech).

Read more

Interested in updates on our
insights, news and testimonials?